Takeda's TAK-881 Matches HYQVIA in Pivotal Phase 2/3 Trial While Halving the Infusion Volume for Primary Immunodeficiency Patients
A 20% subcutaneous immunoglobulin paired with hyaluronidase delivered the same antibody exposure as HYQVIA in half the volume, clearing Takeda's path to global filings in fiscal 2026.